- Home
- ESGL vs UNCY Comparison
ESGL vs UNCY Comparison
Compare ESGL & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESGL | UNCY |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.8M | 141.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ESGL | UNCY |
|---|---|---|
| Price | $3.08 | $6.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 2.5K | ★ 586.8K |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.45 |
| 52 Week High | $4.32 | $7.57 |
Technical Indicators
Market Signals| Indicator | ESGL | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.26 |
| Support Level | N/A | $5.90 |
| Resistance Level | N/A | $6.82 |
| Average True Range (ATR) | 0.00 | 0.36 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 62.83 |
Price Performance
Historical ComparisonAbout ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.